Purchases through the above links give commission which helps fund this website
Recent literature: Dipeptidyl peptidase 4 inhibitor
Date Journal Article title
2020 Mar Int J Mol Sci Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis.
2020 Diabetol Metab Syndr Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes.
2020 Diabetol Int Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular andor kidney disease: group analysis of the randomized CARMELINA® trial.
2020 Mar J Hypertens Increased dipeptidyl peptidase-4 accelerates chronic stress-related thrombosis in a mouse carotid artery model.
2020 Mar ACS Omega Efficient and Straightforward Syntheses of Two United States Pharmacopeia Sitagliptin Impurities: 3-Desamino-2,3-dehydrositagliptin and 3-Desamino-3,4-dehydrositagliptin.
2020 Mar Diabetes Res Clin Pract Sitagliptin Improves Plasma Apolipoprotein Profile in Type 2 Diabetes: A Randomized Clinical Trial of Sitagliptin Effect on Lipid and Glucose Metabolism (SLIM) Study.
2020 Mar Am J Manag Care Cost-effectiveness of diabetes treatment sequences to inform step therapy policies.
2020 Mar Int Immunopharmacol Alogliptin inhibits IL-1β-induced inflammatory response in fibroblast-like synoviocytes.
2020 Mar Diabetes Obes Metab Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin: A analysis from a randomized, placebo-controlled trial (RELEASE study).
2020 Mar Drug Res (Stuttg) Effects of Additional Administration of a Selective Inhibitor of Sodium Glucose co-transporter-2 Inhibitor on the Glycemic Control in Japanese Type 2 Diabetes Mellitus Patients Receiving Treatment with a Dipeptidyl Peptidase-4 Inhibitor.
2020 Hypertension DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.
2020 Mar J Endocrinol Ψ-xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance.
2020 Feb J Clin Med Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan.
2020 Ren Fail Renoprotective effect of vildagliptin following hepatic ischemiareperfusion injury.
2020 J Clin Med Res Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the MuscleFat Ratio in Patients With Type 2 Diabetes.
2020 J Clin Med Res Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial.
2020 Feb Sci Transl Med GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration.
2020 Feb Cardiovasc Diabetol Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
2020 Feb Diabetes Obes Metab Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: The VILDDIAL study, a randomized, multicentre, prospective study.
2020 Feb Diabetes Metab Res Rev Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study.
2020 Feb Diabetes Obes Metab Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease andor kidney disease: A prespecified group analysis of the randomized, placebo-controlled CARMELINA® trial.
2020 Feb BMJ Open Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
2020 PLoS One The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation.
2020 Metab Brain Dis The effects simultaneous inhibition of dipeptidyl peptidase-4 and P2X7 purinoceptors in an in vivo Parkinson's disease model.
2019 Am Health Drug Benefits Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus.
2020 Jan Arch Gerontol Geriatr Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study.
2020 Exp Ther Med Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI.
2020 Feb Endocr J Anagliptin presses diet-induced obesity through enhancing leptin sensitivity and ameliorating hyperphagia in high-fat high-sucrose diet fed mice.
2020 Jan Diabetes Metab Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
2020 Jan Diabetes Res Clin Pract Effectiveness, safety, and tolerability of vildagliptin or vildagliptinmetformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
2020 Jan ESC Heart Fail Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction.
2020 Jan CEN Case Rep Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
2020 Jan Int J Mol Sci Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance through the CXCL12CXCR4mTORTGFβ Signaling Pathway in Breast Cancer Cells.
2020 PLoS One Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
2020 Pharmacol Res Incretins and microRNAs: Interactions and physiological relevance.
2020 Mar Biochem Biophys Res Commun The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
2020 Jan Arch Physiol Biochem Protective effect of saxagliptin against renal ischaemia reperfusion injury in rats.
2020 Jan Sci Rep Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
2020 Mar Biochem Biophys Res Commun Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.
2020 BMJ Open Diabetes Res Care Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene.
2020 BMJ Open Diabetes Res Care Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.
2020 Jan Diabetes Obes Metab Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
2020 Diabetes Ther Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database.
2020 Endocrinol Diabetes Metab The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.
2019 Diabetes Metab Syndr Obes Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus.
2020 Diabetes Res Clin Pract Pharmacological intervention for diabetes after pregnancy prevention in women with prior gestational diabetes: A scoping review.
2020 Jan Prep Biochem Biotechnol A dipyrrole derivative from iAloe verai inhibits an anti-diabetic drug target Dipeptidyl Peptidase (DPP)-IV iin vitroi.
2019 J Obes Metab Syndr Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease.
2020 Thorac Cancer Vildagliptin-induced ground-glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic plementation.
2020 Diabetes Obes Metab Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States.
2020 May Food Chem Integrated approach for obtaining bioactive peptides from whey proteins hydrolysed using a new proteolytic lactic acid bacteria.
2019 Pharm Pract (Granada) Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series.
2019 Diabetol Metab Syndr Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study.
2019 J Clin Exp Hepatol Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.
2020 Cancer Epidemiol Anti-diabetic medications and the risk for colorectal cancer: A population-based nested case-control study.
2020 J Dermatol Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
2019 Dec Biology (Basel) The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin.
2020 Apr Arch Biochem Biophys Teneligliptin prevents doxorubicin-induced inflammation and apoptosis in H9c2 cells.
2020 J Manag Care Spec Pharm Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
2019 PLoS Med Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
2020 Adv Ther Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
2019 Dec BMC Cardiovasc Disord Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis.
2020 Diabetes Ther Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.
2019 Dec Gynecol Endocrinol The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review.
2019 Drugs Context Clinical potential of treatment with semaglutide in type 2 diabetes patients.
2020 Jan Life Sci Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes.
2020 Diabetes Ther Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
2020 Diabetes Ther Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study.
2020 Eur J Clin Pharmacol Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan.
2020 Trends Endocrinol Metab Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
2020 Eur J Heart Fail European Society of CardiologyHeart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
2020 Mayo Clin Proc Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study.
2020 Neurochem Int The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats.
2019 Dec Neurosci Bull DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKTmTOR Pathway and Anti-apoptotic Effects.